OTCMKTS:PKTX ProtoKinetix (PKTX) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free PKTX Stock Alerts $0.02 0.00 (0.00%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$0.0156▼$0.015650-Day Range$0.0142▼$0.019952-Week Range$0.01▼$0.03VolumeN/AAverage Volume144,968 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get ProtoKinetix alerts: Email Address Ad Manward PressShocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.Click here to discover the AI chip company About ProtoKinetix Stock (OTCMKTS:PKTX)ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.Read More PKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PKTX Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comNauticus Robotics And 2 Other Stocks Under $3 Insiders Are BuyingNovember 18, 2023 | finance.yahoo.comProtoKinetix, Incorporated (PKTX)May 8, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.November 12, 2023 | morningstar.comProtoKinetix Inc PKTXOctober 30, 2023 | benzinga.comInsiders Buying ProtoKinetix And 2 Other Stocks Under $2June 6, 2023 | finance.yahoo.comResearch Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for PublicationOctober 10, 2022 | reuters.comPKTX.PK - ProtoKinetix, Inc. | Stock Price & Latest News | ReutersOctober 6, 2022 | benzinga.comProtoKinetix Stock (OTC:PKTX), DividendsMay 8, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.July 20, 2022 | tmcnet.comProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell TransplantsJuly 17, 2022 | uk.investing.comAround $12 Million Bet On Sonim Technologies? 4 Penny Stocks Insiders Are BuyingJuly 15, 2022 | insidermonkey.comHedge Fund and Insider Trading News: Alan Howard, Cathie Wood, Elliott Management, Bridgewater Associates, Sonim Technologies Inc (SONM), ProtoKinetix, Incorporated (PKTX), and MoreJanuary 14, 2022 | finance.yahoo.comProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually OnlyNovember 23, 2021 | finance.yahoo.comProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye DiseaseAugust 9, 2021 | benzinga.com4 Penny Stocks Insiders Are BuyingSee More Headlines Receive PKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProtoKinetix and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:PKTX Previous SymbolNASDAQ:PKTX CUSIPN/A CIK1128189 Webwww.protokinetix.com Phone(330) 445-4971FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Clarence Edward Smith (Age 60)Chairman, President & CEO Mr. Michael Richard Guzzetta CPA (Age 66)Chief Financial Officer Comp: $60kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors PKTX Stock Analysis - Frequently Asked Questions How have PKTX shares performed in 2024? ProtoKinetix's stock was trading at $0.0190 at the beginning of 2024. Since then, PKTX stock has decreased by 17.7% and is now trading at $0.0156. View the best growth stocks for 2024 here. Are investors shorting ProtoKinetix? ProtoKinetix saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 1,600 shares, a decrease of 54.3% from the March 31st total of 3,500 shares. Based on an average daily volume of 130,400 shares, the short-interest ratio is currently 0.0 days. View ProtoKinetix's Short Interest. What other stocks do shareholders of ProtoKinetix own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProtoKinetix investors own include Fulcrum Therapeutics (FULC), Rockwell Medical (RMTI), Provention Bio (PRVB), VIVUS (VVUS), Actinium Pharmaceuticals (ATNM), Chimerix (CMRX), Rexahn Pharmaceuticals (REXN), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). How do I buy shares of ProtoKinetix? Shares of PKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PKTX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024Altimetry[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProtoKinetix, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.